Skip to main content
MIR logo

MIR · Mirion Technologies, Inc.

Track MIR — free
$16.78 -0.26 (-1.53%)
Market Cap
$4.18B
Shares
245.49M
Volume · Nov 17 1.38M Avg daily vol (3M) 4.27M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$17.04 Open$17.30 Day$17.03–17.76 52W close$14.12–27.00 Avg vol 30d5.0M Short int35.7M · 14.6% of shares · 7.2d Short vol59% Last earningsOct 28, 2026 DataAug 2020–Nov 2026 Filing10-Q · Oct 28

Up next

Feb 10, 2027 Est · unconfirmed · in 12 wks

Latest documents

2026
Nov 10
Investor event
Nuclear power grew 14% as orders rose 62%

Mirion reported third-quarter organic orders growth of 62% and organic revenue growth of 6.5%, with nuclear power up 14%. Management sees durable nuclear demand and normalization across medical markets.

4 source passages
62% organic orders growth, overall organic revenue growth accelerated to 6.5%, strengthened nuclear power end market specifically with 14% organic growth. Mirion is the global leader in ionizing radiation detection and measurement the conditions feel durable to us we are beginning, in our view, to see a normalization of the post-COVID dynamic that has created a bit of flatness and growth overall in the med tech sector Open the document at this passage
Oct 28
Earnings call
Q3 2026 earnings call

Mirion Technologies, Inc. raised full-year 2026 revenue growth guidance to 24% to 25%, organic revenue growth guidance to 7% to 8%, and adjusted free cash flow guidance to $170 million to $185 million, while withdrawing its previously announced 2028 margin target.

Oct 28
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly report for FY2026 Q3

Mirion Technologies reported third-quarter revenues of $277.8 million, up from $223.1 million, net income of $7.8 million versus $3.1 million, and backlog of $1,248.2 million at September 30, 2026. Nuclear & Safety generated 69.8% of quarterly revenue.

Revenue $277.8M ▲ 24.5% Net income $7.4M ▲ 155.2% Diluted EPS $0.03 ▲ 200.0%
Read from the MD&A section
Oct 27
Current report 8-K
Financial results

Mirion Technologies, Inc. reported third-quarter revenue of $277.8 million, up 24.5%, and Adjusted EBITDA of $64.8 million, up 23.7%. It revised 2026 revenue growth guidance to approximately 24% – 25%.

Aug 31
Current report 8-K
Other events AI summary on its way
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.08B
Trailing 12 months
Net income (TTM)
$28.70M
Trailing 12 months
Revenue growth YoY
+24.5%
Year over year
Operating margin
6.0%
Trailing 12 months
P / E (TTM)
147.8
Trailing earnings · reciprocal yield 0.7%
FCF yield
4.0%
TTM · current market cap
Return on invested capital
2.7%
Trailing 12 months
Net cash
−$35.30M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+6.7%
Year over year · more shares
Price change (1Y)
-31.6%
Trailing year
Short interest
14.6%
Latest settlement · 7.2 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Jul 29, 2026
Q2 FY26

TL;DR. Mirion reported Q2 revenue up 19.7% to $266.8M with adjusted EBITDA up 27.5% and reaffirmed full-year 2026 guidance, while Q2 orders grew 40% to $291M with backlog up nearly 40% year-over-year, but the medical segment saw end-market guides lowered and a Chinese new-build order was cancelled.

Bullish
  • + Backlog grew nearly 40% year-over-year to over $1.1 billion in Q2 2026.
  • + Q2 orders grew 40% to $291M, with nuclear power orders excluding M&A up approximately 50%.
  • + Q2 adjusted EBITDA grew 27.5% to $65.3M with margins expanding across both segments.
  • + Company reaffirmed full-year 2026 guidance including ~22-24% revenue growth and $285-300M adjusted EBITDA.
  • + Raised RTQA full-year organic growth outlook to double digits from prior mid-single-digit-plus guide.
Bearish
  • − Medical segment Q2 organic revenue declined 1%, below prior expectations of low-single-digit growth.
  • − Lowered nuclear medicine full-year guide to mid-single digits from prior double-digit guide due to delayed hardware demand.
  • − Lowered dosimetry full-year outlook to negative organic growth from prior flat guide.
  • − Q2 organic revenue grew only 1%, held back by difficult comps, with first-half organic growth at 2% versus full-year guide of 5-7%.
  • − Chinese new-build order cancellation booked in 2019, with potential contract negotiations ahead.
  • − Nuclear power Q2 revenue was flat organically as growth in installed base and SMRs was offset by less new build revenue.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Neutral Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 22.9 · elevated Equity put/call 0.73
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −5%
below
Price vs 50-day avg +4%
above
RSI (14) 49
neutral
MACD trend Negative
52-week position 23%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Neutral
1-month return +14%
trailing
6-month return 0%
trailing
YTD return −27%
this year
Relative strength +2%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $16 › 200d $18 — 200d above 50d
Institutional flow Distributing
-2% holders QoQ · +47 funds added
Insider flow Accumulating
Net +$312.0K over 90 days · 0% sells
Short interest Falling
14.56% of shares out · ▼ -13.2% MoM · 7.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
354 holders — mid 3-yr range
Squeeze score 66
elevated · 0–100
Fundamentals
Strong
Revenue growth +8%
Y/Y
Gross margin 47%
expanding
EPS growth +161%
Y/Y
Free cash flow $106.9M
Valuation P/E 142
rich
Buyback $250.0M
authorized
Balance sheet $32.4M
net debt
Quant / Vol
risk profile
Very High
Volatility 52%
annualized · 1-yr
Max drawdown −48%
past year
ATR 5.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Jul 29, 2026
back half
Organic revenue Non-GAAP 7.5% – 11.2%
second half of the year
Adjusted EBITDA margins Non-GAAP 27% – 29%
Adjusted free cash flow Non-GAAP $95M – $115M
Organic revenue growth Non-GAAP 7.5% – 11.2%
Previous outlook earlier release · from the 8-K filed Jul 28, 2026

Still-open targets the latest release did not restate under the same label.

Revenue growth · fiscal year ending December 31, 2026 22% – 24%
Organic Revenue growth · fiscal year ending December 31, 2026 5% – 7%
Adjusted EBITDA · fiscal year ending December 31, 2026 $285M – $300M
Adjusted EBITDA margin · fiscal year ending December 31, 2026 25% – 26%
Adjusted Free Cash Flow Conversion · fiscal year ending December 31, 2026 54% – 58%
Adjusted Free Cash Flow · fiscal year ending December 31, 2026 $155M – $175M
Adjusted EPS · fiscal year ending December 31, 2026 $0.48 – $0.55

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 5 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−5% Neutral
Price vs 50-day avg
+4% Bullish
RSI (14)
49 Neutral
MACD trend
Negative Bearish
52-week position
23% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $16 › 200d $18 — 200d above 50d
Institutional flow Distributing
-2% holders QoQ · +47 funds added
Insider flow Accumulating
Net +$312.0K over 90 days · 0% sells
Short interest Falling
14.56% of shares out · ▼ -13.2% MoM · 7.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
354 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $14 Now $17 · 23% Range high $27
vs 200-day avg -5% vs 50-day avg +4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Specialty Industrial Machinery — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MIR
Mirion Technologies, Inc.
this stock
$4.18B -27.2% +7.5% 142.0 14.6%
GEV
GE Vernova Inc.
$202.10B +16.8% +9.0% 20.1 2.8%
ETN
Eaton Corp plc
$130.88B +5.8% +10.3% 33.7 1.8%
SMERY
Siemens Energy AG
$118.69B — — — 0.0%
PH
Parker-Hannifin Corp
$117.88B +6.4% +18.9% 32.1 1.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
354
% held
110.4%
Net QoQ
+8.9M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
376
View
Short & Settlement
Short Interest Falling
Shares short
35.7M
Days to cover
7.2d
Change
-5.5M sh
View
Short Volume
Short vol %
59%
As of
Nov 16, 2026
Short Total
View
Fails to Deliver
FTD shares
455
Value
$8.5K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
39.3%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$312.0K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$925.4M
Net income (FY)
$28.8M
EPS diluted
$0.11
View
Buybacks
Authorized
$250.0M
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 10, 2026
This year
16

Mirion reported third-quarter organic orders growth of 62% and organic revenue growth of 6.5%, with nuclear power up 14%. Management sees durable nuclear demand and normalization across medical markets.

View
Proposed Sales
Value
$165.0K
Shares
8.4K
Filed
May 7, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 10, 2026
View
Investor Relations
Latest news
Mirion Announces Third Quarter 20…
Published
Oct 27, 2026
View

Performance

5D 20D 120D MTD YTD
MIR -12.5% +14.1% +0.5% -7.2% -27.2%
SPY -1.7% -3.5% -1.4% -2.1% +8.5%
vs SPY -10.8% +17.6% +1.9% -5.2% -35.8%

Capital returns

Buyback program · as of Aug 31, 2026
Authorized
$250.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1809987 CUSIP 60471A101 13F (30d) 360 filings 331 filers Visit website Investor relations